title: Interaction effects of lead on bioavailability and pharmacokinetics of arsenic in the rat.
abstract: Arsenic (As) and lead (Pb) are common contaminants found in mine waste materials. For an evidence-based risk assessment, it is important to better understand the potential interaction of mixed contaminants; and this interaction study was investigated in an in vivo rat model. Following co-administration of a fixed dose of As(V) as in sodium arsenate and different doses of Pb as lead acetate to Sprague-Dawley rats, blood arsenic concentration and bioavailability decreased. A decrease in As blood concentration when lead was co-administered was observed with increasing lead doses. Pharmacokinetic parameters for As in the blood showed faster absorption and elimination of this metalloid in the presence of Pb. The elimination half-life of As decreased from 67 days in As solo group to 27-30 with doses of Pb. Bioavailability of As was also decreased by 30-43 % in the presence of Pb. Decreased urinary excretion of Pb and tissue accumulation were also observed. It indicates lower absorption of As when co-administered with Pb. A probable explanation for these findings is that As co-administration with Pb could have resulted in the formation of less soluble lead arsenate. However, such an interaction between As and Pb could only explain about one-third of the variation when real mine waste materials containing both of these elements were administered to rats. This suggests that other effects from physical and chemical parameters could contribute to the bioavailability of arsenic in complex real environmental samples.
authors.affiliation: National Research Centre for Environmental Toxicity, The University of Queensland, 39 Kessels Rd, Coopers Plains, Brisbane, QLD, 4108, Australia, v.diacomanolis@uq.edu.au.
authors.forename: Violet
authors.initials: V
authors.lastname: Diacomanolis
authors.forename: Barry N
authors.initials: BN
authors.lastname: Noller
authors.forename: Jack C
authors.initials: JC
authors.lastname: Ng
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001149:Arsenates / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics / Q000652:urine; D001315:Australia; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D004781:Environmental Exposure; D013058:Mass Spectrometry; D009942:Organometallic Compounds / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D012989:Soil Pollutants / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics / Q000652:urine
chemical_list: D001149:Arsenates; D009942:Organometallic Compounds; D012989:Soil Pollutants; C009277:sodium arsenate; C008261:lead acetate